500 related articles for article (PubMed ID: 33301499)
21. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
[TBL] [Abstract][Full Text] [Related]
22. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
[TBL] [Abstract][Full Text] [Related]
23. Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.
Celli R; Saffo S; Kamili S; Wiese N; Hayden T; Taddei T; Jain D
Arch Pathol Lab Med; 2021 Apr; 145(4):419-427. PubMed ID: 32810870
[TBL] [Abstract][Full Text] [Related]
24. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
25. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
[TBL] [Abstract][Full Text] [Related]
26. HCV Eradication in Primary or Secondary Prevention Optimizes Hepatocellular Carcinoma Curative Management.
Nahon P; Layese R; Cagnot C; Asselah T; Guyader D; Pol S; Pageaux GP; De Lédinghen V; Ouzan D; Zoulim F; Audureau E;
Cancer Prev Res (Phila); 2021 May; 14(5):581-592. PubMed ID: 33608313
[TBL] [Abstract][Full Text] [Related]
27. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
29. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
[TBL] [Abstract][Full Text] [Related]
30. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
31. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
[TBL] [Abstract][Full Text] [Related]
32. HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
Semmler G; Meyer EL; Kozbial K; Schwabl P; Hametner-Schreil S; Zanetto A; Bauer D; Chromy D; Simbrunner B; Scheiner B; Stättermayer AF; Pinter M; Schöfl R; Russo FP; Greenfield H; Schwarz M; Schwarz C; Gschwantler M; Alonso López S; Manzano ML; Ahumada A; Bañares R; Pons M; Rodríguez-Tajes S; Genescà J; Lens S; Trauner M; Ferenci P; Reiberger T; Mandorfer M
J Hepatol; 2022 Apr; 76(4):812-821. PubMed ID: 34871626
[TBL] [Abstract][Full Text] [Related]
33. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
34. Association between Liver Stiffness and Liver-Related Events in HCV-Infected Patients after Successful Treatment with Direct-Acting Antivirals.
Rodprasert N; Hongboontry T; Cherdchoochart C; Chaiteerakij R
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984603
[No Abstract] [Full Text] [Related]
35. Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virological response.
Peleg N; Issachar A; Sneh Arbib O; Cohen-Naftaly M; Harif Y; Oxtrud E; Braun M; Leshno M; Barsheshet A; Shlomai A
J Viral Hepat; 2019 Nov; 26(11):1257-1265. PubMed ID: 31243878
[TBL] [Abstract][Full Text] [Related]
36. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
37. Late development of hepatocellular carcinoma after viral clearance in patients with chronic hepatitis C: A need for continual surveillance.
Tong MJ; Theodoro CF; Salvo RT
J Dig Dis; 2018 Jul; 19(7):411-420. PubMed ID: 29889353
[TBL] [Abstract][Full Text] [Related]
38. Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV).
Quaranta MG; Cavalletto L; Russo FP; Calvaruso V; Ferrigno L; Zanetto A; Mattioli B; D'Ambrosio R; Panetta V; Brancaccio G; Raimondo G; Brunetto MR; Zignego AL; Coppola C; Iannone A; Biliotti E; Rosselli Del Turco E; Massari M; Licata A; Barbaro F; Persico M; Morisco F; Pompili M; Cerini F; Puoti M; Santantonio T; Craxì A; Kondili LA; Chemello L; On Behalf Of Piter Collaborating Investigators
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793565
[TBL] [Abstract][Full Text] [Related]
39. Noninvasive assessment of liver fibrosis can predict clinical outcomes at late follow-up after a sustained virological response in HCV patients?
Ragazzo TG; Zitelli PMY; Mazo DF; Oliveira CP; Carrilho FJ; Pessoa MG
Clinics (Sao Paulo); 2024; 79():100381. PubMed ID: 38733689
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Hepatocellular Carcinoma Development in Korean Patients after Hepatitis C Cure with Direct-Acting Antivirals.
Hong H; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
Gut Liver; 2024 Jan; 18(1):147-155. PubMed ID: 37076993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]